Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics develops radiopharmaceutical candidates for cancer using proprietary Lead-212 (212Pb) technology and specialized targeting moieties. Its updates center on a theranostic approach that pairs targeted alpha therapy with complementary imaging diagnostics.
Recurring CATX news covers clinical and conference updates for VMT-α-NET in SSTR2-expressing neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors, along with business results, financing activity, manufacturing infrastructure, 212Pb generator-enabled finishing facilities, and corporate presentations.
Perspective Therapeutics (NYSE American: CATX) reported 1Q 2026 results and business updates. The company is advancing three clinical-stage 212Pb radiopharmaceutical programs (VMT-α-NET, VMT01, PSV359) with multiple 2026 data milestones, expanding a regional manufacturing network, and progressing preclinical asset PSV594.
Cash, equivalents, and short-term investments were $271M at March 31, 2026, supported by a February underwritten offering with $164M net proceeds, providing cash runway into late 2027. R&D expenses rose to $21.4M, G&A fell to $7.0M, and net loss was $26.2M ($0.25/share).
Perspective Therapeutics (NYSE AMERICAN: CATX) will deliver multiple corporate updates and investor events in May 2026, including an analyst event, a press-release-only first quarter 2026 financial results posting, and two conference fireside chats.
Key dates: May 4 analyst event at 8:30 a.m. ET; May 11 Q1 2026 press release after market close; May 13 BofA fireside chat at 2:20 p.m. PT; May 19 RBC fireside chat at 2:05 p.m. ET. Webcasts will be posted on the company website unless noted.
Perspective Therapeutics (NYSE AMERICAN: CATX) presented updated interim Phase 1/2a data for [212Pb]VMT-α-NET at AACR 2026 with a March 4, 2026 data cut. Safety from 64 treated patients showed no dose‑limiting toxicities, no Grade 5 events, and 36% with Grade ≥3 TEAEs. Efficacy analysis (25 patients) reported 43% objective response in Cohort 2 and 72% progression‑free/alive at update.
The company plans additional cohorts, subgroup analyses, and further efficacy data later in 2026 to support regulatory engagement and conference presentations.
Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will participate in investor events in April 2026. Key appearances include a presentation and fireside chat at the Needham Virtual Healthcare Conference on April 14, 2026 (9:30–10:10 a.m. ET) and one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston.
Management will be available for investor 1x1 meetings; times and virtual access details follow each conference schedule.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated data for its [212Pb]VMT-α-NET program were accepted as a poster presentation at the AACR Annual Meeting 2026 in San Diego, April 17–22, 2026.
The poster, by Thorvardur Halfdanarson from Mayo Clinic, reports safety and preliminary efficacy from dose‑finding cohorts 1–3 in advanced SSTR2+ neuroendocrine tumors and is scheduled for April 20, 2026, 9:00 am–12:00 pm, Abstract CT088.
Perspective Therapeutics (NYSE AMERICAN: CATX) reported full year 2025 results and a business update on March 16, 2026. Key clinical updates: VMT-α-NET shows favorable tolerability, no DLTs across dose levels, and 76% of 25 efficacy-evaluable patients were progression-free at updated follow-up.
Financials: cash and short-term investments of ~$145M as of December 31, 2025, plus ~$164M net proceeds from a February 2026 equity offering, expected to fund operations into late 2027. 2025 net loss was $103.1M; R&D expense rose ~102% to $84.2M.
Perspective Therapeutics (NYSE AMERICAN: CATX) will report full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The company said the results and update will be posted on its newsroom press releases page.
Investors can expect a webcast or press release posting following the market close on that date.
Perspective Therapeutics (NYSE AMERICAN: CATX) priced an underwritten offering to raise approximately $175 million of gross proceeds by selling 39,576,088 common shares at $3.79 per share and pre-funded warrants to purchase 6,598,046 shares at $3.789 each. The offering is expected to close on or about February 3, 2026, subject to customary closing conditions.
Perspective said it will use net proceeds to advance clinical development, invest in manufacturing facilities, and for working capital and general corporate purposes; a portion may be used for acquisitions or licenses though no commitments exist.
Perspective Therapeutics (NYSE AMERICAN: CATX) provided clinical and operational updates ahead of its J.P. Morgan presentation on January 14, 2026 at 2:15 p.m. PT. Key points: updated [212Pb]VMT-α-NET data (DCO Dec 10, 2025) show no DLTs in a 56-patient safety set and durable disease control in an efficacy subset (19/25 without progression). Cohort 3 DLT assessment is complete and enrollment continues. VMT01 and PSV359 remain in early dose-finding stages with additional clinical readouts expected mid–late 2026. Manufacturing capacity expansion is underway.
Perspective Therapeutics (NYSE:CATX) reported updated interim Phase 1/2a data for [212Pb]VMT-α-NET with a data cut-off of December 10, 2025. Safety analysis covered 56 patients across three dose cohorts (2.5, 5.0, 6.0 mCi) with no DLTs, no treatment-related discontinuations, and no Grade 5 events; Grade ≥3 events occurred in 21 patients (37.5%) and one transient Grade 4 lymphopenia resolved. Efficacy analysis in 25 patients (2 in Cohort 1; 23 in Cohort 2) showed 9/23 (39%) objective responses in Cohort 2 (8 confirmed previously) and 19/25 (76%) without progression and alive at update. Cohort 3 DLT assessment completed and additional enrollment cleared.